PE20181002A1 - Derivados del acido 5-(n- bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana - Google Patents

Derivados del acido 5-(n- bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana

Info

Publication number
PE20181002A1
PE20181002A1 PE2018000174A PE2018000174A PE20181002A1 PE 20181002 A1 PE20181002 A1 PE 20181002A1 PE 2018000174 A PE2018000174 A PE 2018000174A PE 2018000174 A PE2018000174 A PE 2018000174A PE 20181002 A1 PE20181002 A1 PE 20181002A1
Authority
PE
Peru
Prior art keywords
acid
alkyl
benzyl
tetrahidroisoquinolin
acetico
Prior art date
Application number
PE2018000174A
Other languages
English (en)
Inventor
Kyle J Eastman
John F Kadow
Kyle E Parcella
B Narasimhulu Naidu
Tao Wang
Zhiwei Yin
Zhongxing Zhang
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56851651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181002(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of PE20181002A1 publication Critical patent/PE20181002A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion refiere un compuesto de formula I : En donde: R1 esta seleccionado de H, alquilo o cicloalquilo; R2 esta seleccionado de tetrahidroisoquibolinilo y esta sustituido con 1 sustituyente R6; R3 esta seleccionado de azetidinilo, pirrolidinilo, piperazinilo, entre otros; R4 es alquilo o haloalquilo; R5 es alquilo; R6 esta seleccionado de Ar1, (Ar1)alquilo, entre otros. Ar1 es fenilo sustituido con 0-5 sustituyentes seleccionados de ciano, halo, alquilo, entre otros. Son compuestos preferidos: acido (S)-2-(terc-butoxi)-2-(4-(4,4-dimetilpiperidin-1-il)-5-(2-(4-fluorobencil)-1,2,3,4-tetrahidroisoquinolin-6-il)-2,6-dimetilpiridin-3-il)acetico; : acido (S)-2-(terc-butoxi)-2-(4-(4,4-dimetilpiperidin-1-il)-2,6-dimetil-5-(2-(3-(trifluorometil)bencil)-1,2,3,4-tetrahidroisoquinolin-6-il)-2,6-dimetilpiridin-3-il)acetico, entre otros. La presente invencion es util para la inhibicion del VIH y tratamiento de los infectados con VIH y SIDA.
PE2018000174A 2015-08-11 2016-08-10 Derivados del acido 5-(n- bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana PE20181002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562203791P 2015-08-11 2015-08-11

Publications (1)

Publication Number Publication Date
PE20181002A1 true PE20181002A1 (es) 2018-06-26

Family

ID=56851651

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000174A PE20181002A1 (es) 2015-08-11 2016-08-10 Derivados del acido 5-(n- bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana

Country Status (23)

Country Link
US (2) US10189816B2 (es)
EP (1) EP3334716A1 (es)
JP (1) JP6782766B2 (es)
KR (1) KR20180032649A (es)
CN (1) CN108137534A (es)
AR (1) AR105653A1 (es)
AU (1) AU2016306089B2 (es)
CA (1) CA2994791A1 (es)
CL (1) CL2018000363A1 (es)
CO (1) CO2018001359A2 (es)
CR (1) CR20180091A (es)
DO (1) DOP2018000035A (es)
EA (1) EA033057B1 (es)
HK (1) HK1249503A1 (es)
IL (1) IL257240B (es)
MA (1) MA42614A (es)
MX (1) MX2018001722A (es)
PE (1) PE20181002A1 (es)
PH (1) PH12018500294A1 (es)
TW (1) TWI657086B (es)
UA (1) UA120464C2 (es)
WO (1) WO2017025917A1 (es)
ZA (1) ZA201800689B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522913A (ja) * 2015-08-12 2018-08-16 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−［６，５］−縮合二環式アリールテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
JP2019515003A (ja) * 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
US20200325127A1 (en) * 2016-05-11 2020-10-15 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3455214A1 (en) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
UY37555A (es) * 2017-01-03 2018-08-31 Viiv Healthcare Uk No 5 Ltd Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
JP2020503352A (ja) * 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CA2705318C (en) * 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2009062288A1 (en) 2007-11-15 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
ES2463720T3 (es) 2007-11-16 2014-05-29 Gilead Sciences, Inc. Inhibidores de la replicación del virus de inmunodeficiencia humana
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
KR101483834B1 (ko) 2009-12-23 2015-01-16 카트호리이케 유니버시타이트 로이펜 항바이러스 화합물
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014164467A1 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9527842B2 (en) 2013-03-14 2016-12-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3116880B1 (en) * 2014-02-20 2018-03-21 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
US10214516B2 (en) * 2015-08-12 2019-02-26 VIIV Healthcare UK (No.5) Limited 5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP2018522913A (ja) * 2015-08-12 2018-08-16 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−［６，５］−縮合二環式アリールテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体

Also Published As

Publication number Publication date
CN108137534A (zh) 2018-06-08
JP6782766B2 (ja) 2020-11-11
CL2018000363A1 (es) 2018-07-06
WO2017025917A1 (en) 2017-02-16
CR20180091A (es) 2018-06-13
DOP2018000035A (es) 2018-03-30
CO2018001359A2 (es) 2018-05-10
AU2016306089A1 (en) 2018-03-01
US10189816B2 (en) 2019-01-29
MX2018001722A (es) 2018-05-16
HK1249503A1 (zh) 2018-11-02
US20180230129A1 (en) 2018-08-16
EP3334716A1 (en) 2018-06-20
UA120464C2 (uk) 2019-12-10
US20190092754A1 (en) 2019-03-28
TW201718549A (zh) 2017-06-01
IL257240B (en) 2020-02-27
IL257240A (en) 2018-03-29
MA42614A (fr) 2021-05-26
AU2016306089B2 (en) 2018-08-09
EA033057B1 (ru) 2019-08-30
PH12018500294A1 (en) 2018-08-13
AR105653A1 (es) 2017-10-25
TWI657086B (zh) 2019-04-21
ZA201800689B (en) 2021-08-25
JP2018522927A (ja) 2018-08-16
CA2994791A1 (en) 2017-02-16
EA201890361A1 (ru) 2018-11-30
KR20180032649A (ko) 2018-03-30

Similar Documents

Publication Publication Date Title
PE20181002A1 (es) Derivados del acido 5-(n- bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20210642A1 (es) Inhibidores de pd-1/pd-l1
PE20211472A1 (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas
PE20160843A1 (es) Pirrolidinonas herbicidas
AR101788A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
PE20151538A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20170939A1 (es) Pirimidinonas como inhibidores del factor xia
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20170331A1 (es) Derivados quinolina como inhibidores smo
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
MX2022008434A (es) Herbicidas de piridazinona.
AR101586A1 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
NZ732657A (en) Picolinamides with fungicidal activity and other related compounds
BR112017006251A2 (pt) novos compostos
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
NZ631762A (en) 5-membered heteroaryls and their use as antiviral agents
AR106778A1 (es) Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre y ciclopropilo
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
AR091285A1 (es) Inhibidores de bromodominio y sus usos
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
NZ732812A (en) Use of picolinamides and other compounds as fungicides
PE20140171A1 (es) Pirazoles fungicidas y sus mezclas
PE20181074A1 (es) Compuestos heteroaromaticos como inhibidores de btk